🔴 Neurosense Therapeutics is trading 8.86% down today after its 1-for-20 reverse stock split took effect

Neurosense Therapeutics is trading 8.86% down now at $6.11 after its 1-for-20 reverse stock split became effective September 14, 2026.

• Nasdaq confirmed the consolidation and associated CUSIP change, making this the clearest company-specific catalyst for the decline.
• Broader risk-off conditions may be adding pressure: S&P 500 down 0.77% and Nasdaq Composite down 1.07%.
• Management is scheduled to present at the H.C. Wainwright conference on September 15, 2026; no new clinical or financial announcement was identified.